Company

Our U.S. Legacy

Updated as of April 29, 2025

Soon after its founding, Biogen relocated to the United States in the early 1980s and established its roots in Cambridge, Massachusetts by opening a research center, manufacturing factory, and headquarters in Kendall Square. Nearly 50 years later, Biogen has helped create and strengthen what has become the world’s leading center for biotech research and innovation.

In addition to our global headquarters and commercial operations, the United States is the home of our main innovation hubs with close to 2,500 employees working in research and development (R&D), manufacturing, and pharmaceutical and technical operations.

Biogen R&D teams in the United States are primarily located in Cambridge, MA and we recently expanded to South San Francisco, CA with the creation of a West Coast Hub. The company’s largest manufacturing campuses are in Wake and Durham counties in North Carolina. In 2024, about three-quarters of U.S. product revenue was generated by products which have manufacturing operations in the United States.

In 2025, Biogen announced its plans for a new global headquarters in Cambridge, MA. Scheduled to open when Biogen celebrates its 50th anniversary in 2028, the new state-of-the-art facility will commemorate five decades of excellence in scientific discovery, clinical development, and delivering innovative new treatments.

Our U.S. manufacturing footprint

Biogen's largest manufacturing footprint is located in North Carolina’s Research Triangle Park (RTP). As the state's largest biotech employer and one of the top five biopharmaceutical employers, Biogen employs over 1,500 people and more than 400 skilled contractors across its Wake County and Durham County campuses.

Our manufacturing operations in North Carolina include seven manufacturing factories across multiple modalities that produce complex high-quality medicines for the U.S. market and rest of the world. An eighth factory is currently under construction and is expected to be operational in the second half of 2025. We are also in the process of transferring ex-US manufacturing of products acquired from recent company transactions to our North Carolina factories.

In addition to state-of the-art manufacturing, our North Carolina campuses include sophisticated quality control laboratories to ensure the safety, efficacy, and purity of the medicines we produce.

More than 90% of innovator commercial medicines produced by Biogen have manufacturing and quality control testing in the U.S. Additionally, we export 80% of active product produced in the United States to global markets.

Our U.S. research and development capabilities

70% of Biogen’s research and development employees are based in the United States, primarily at our global innovation hub in Cambridge, MA. Recently, we also added a new R&D hub in South San Francisco, CA.

In 1998, Biogen received the U.S. National Medal of Technology and Innovation, granted by the President of the United States. The National Medal of Technology and Innovation is the highest honor for technological achievement in the United States. Building on the legacy of our two Nobel Prize-winning founders, we focus on difficult-to-treat diseases where there are no or few treatment options.

Biogen’s recent breakthrough innovations include the first treatments for spinal muscular atrophy, Alzheimer’s disease, ALS-SOD1, postpartum depression and Friedreich ataxia. All of these medicines were primarily researched and developed in the United States and help thousands of patients today in the United States and globally.

Biogen has more than 20 clinical trials ongoing in the United States, engaging over 370 different sites across the country.

Our U.S. citizenship responsibility

From 2021 to 2024 Biogen paid over $2 billion in federal, state, and local taxes in the U.S. Our profits from the U.S. market revenues are almost entirely taxable in the U.S. at the full federal and state tax rates.

We also comply with local taxes for the revenues we generate outside the United States. As a result, Biogen's effective tax rate reflects the geographic business mix of the company based on taxable profits in each market.

Biogen generates a relatively high percentage of revenue outside the United States. This revenue is taxable in those local markets under the US GILTI regime led from our hub in Switzerland.

In the past 10 years, approximately 95% of the Biogen Foundation grants and employee matching gift donations have been allocated to U.S. not-for-profit organizations, focusing on education, food security, and access to medicines.

U.S Key figures

More than half of our 7,000 employees are based in the United States.

70% of Biogen’s employees working in R&D, manufacturing and technical operations are based in the United States.

More than 20 clinical trials are ongoing in the United States.

3 innovation hubs (Cambridge, MA; Research Triangle Park, NC and South San Francisco, CA).

580,000-square-feet of office and research and development lab planned for new global headquarter and innovation hub to open in Kendall Square, MA in 2028.